ID: ALA5199320

Max Phase: Preclinical

Molecular Formula: C97H142N28O26S4

Molecular Weight: 2244.64

Representations

Canonical SMILES:  CC(C)C[C@@H]1NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(=N)N)CSCC(=O)CSC[C@@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H]2CSCC(=O)CSC[C@@H](C(=O)N3CCC[C@H]3C(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC2=O)[C@@H](C)O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC1=O

Standard InChI:  InChI=1S/C97H142N28O26S4/c1-49(2)33-64-84(139)117-67(36-54-38-108-60-19-9-8-17-58(54)60)86(141)122-72(47-154-42-56(129)41-153-46-71(120-80(135)59(99)18-12-30-106-96(102)103)91(146)114-63(27-28-75(100)131)81(136)109-39-77(133)111-64)92(147)116-66(34-52-15-6-5-7-16-52)88(143)124-78(51(4)127)93(148)119-69(40-126)89(144)118-68(37-76(101)132)87(142)113-61(20-10-11-29-98)82(137)115-65(35-53-23-25-55(128)26-24-53)85(140)121-70-45-152-43-57(130)44-155-48-73(94(149)125-32-14-22-74(125)95(150)151)123-83(138)62(21-13-31-107-97(104)105)112-79(134)50(3)110-90(70)145/h5-9,15-17,19,23-26,38,49-51,59,61-74,78,108,126-128H,10-14,18,20-22,27-37,39-48,98-99H2,1-4H3,(H2,100,131)(H2,101,132)(H,109,136)(H,110,145)(H,111,133)(H,112,134)(H,113,142)(H,114,146)(H,115,137)(H,116,147)(H,117,139)(H,118,144)(H,119,148)(H,120,135)(H,121,140)(H,122,141)(H,123,138)(H,124,143)(H,150,151)(H4,102,103,106)(H4,104,105,107)/t50-,51+,59-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,78-/m0/s1

Standard InChI Key:  PFXDBMLKDZLRSP-GFXCSZQDSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 2244.64

Molecular Weight (Monoisotopic): 2242.9533

AlogP:

#Rotatable Bonds:

Polar Surface Area:

Molecular Species:

HBA:

HBD:

#RO5 Violations:

HBA (Lipinski):

HBD (Lipinski):

#RO5 Violations (Lipinski):

CX Acidic pKa:

CX Basic pKa:

CX LogP:

CX LogD:

Aromatic Rings:

Heavy Atoms:

QED Weighted:

Np Likeness Score:

References

1. Carle V, Wu Y, Mukherjee R, Kong XD, Rogg C, Laurent Q, Cecere E, Villequey C, Konakalla MS, Maric T, Lamers C, Díaz-Perlas C, Butler K, Goto J, Stegmayr B, Heinis C..  (2021)  Development of Selective FXIa Inhibitors Based on Cyclic Peptides and Their Application for Safe Anticoagulation.,  64  (10.0): [PMID:33974422] [10.1021/acs.jmedchem.1c00056]

Source

Source(1):

• Scientific Literature